CORRECT(6/27): Business Leaders Urge G-20 To Focus On Sustaining Global Economy
28th Jun 2010 17:21
("=Business Leaders Urge G-20 To Focus On Sustaining Global Economy," published Sunday, incorrectly listed Archer Daniels Midland Co.'s Patricia Woertz as an attendee in paragraph 5. The correct version follows:) By Caroline Van Hasselt Of DOW JONES NEWSWIRES TORONTO (Dow Jones)--A h
Read moreBusiness Leaders Urge G-20 To Focus On Sustaining Global Economy
27th Jun 2010 18:34
By Caroline Van Hasselt Of DOW JONES NEWSWIRES TORONTO (Dow Jones)--A high-powered group of the corporate leaders urged Group of 20 nations to focus on shaping policies that sustain the global economy rather than respond to populism aimed at punishing business, the Canadian Council of Chief
Read moreUPDATE: WellPoint's Data Led It To Limit Use Of Drug Boniva
25th Jun 2010 03:24
(Adds Genentech comment in sixth and 11th paragraphs, notes in fourth paragraph that change applies to patients covered through WelPoint's commercial plans.) By Dinah Wisenberg Brin Of DOW JONES NEWSWIRES WellPoint Inc. (WLP), the largest U.S. managed-care concern by membership, made it
Read moreUPDATE: Merck: South Africa Venture, FDA Asthma Drug Approval
24th Jun 2010 22:42
(Updates with analyst comments, beginning in the third paragraph.) By Nathan Becker and Shara Tibken Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--Merck & Co. (MRK) announced it was collaborating with South African company Adcock Ingram Holdings Ltd. (AIP.JO) to promote and distribute pro
Read moreWellPoint's Internal Data Led It To Limit Use Of Drug Boniva
24th Jun 2010 21:08
By Dinah Wisenberg Brin Of DOW JONES NEWSWIRES WellPoint Inc. (WLP), the largest U.S. managed-care concern by membership, made it harder last year for its members to gain approval for use of the Boniva osteoporosis drug after internal research linked it to higher fracture rates, lower patien
Read moreUPDATE: "Printed" Drugs Promised From Glaxo's Academic Project
24th Jun 2010 17:18
(Adds background.) By Sten Stovall Of DOW JONES NEWSWIRES LONDON (Dow Jones)--A collaboration between GlaxoSmithKline PLC (GSK) and two U.K. universities is developing technology aimed at turning tiny but powerful pharmaceutical compounds into innovative medicines by printing them on a p
Read moreUPDATE: SkyePharma Falls On Latest Flutiform Blow
24th Jun 2010 15:16
(Adds detail and analyst comment.) By Jason Douglas Of DOW JONES NEWSWIRES LONDON (Dow Jones)--Shares in SkyePharma PLC (SKP.LN) fell to a new low Thursday after the drug developer said its hopes of launching asthma treatment Flutiform in the U.S. were dealt what's likely to be a final blo
Read more"Printed" Drugs Promised From Glaxo Academic Collaboration
24th Jun 2010 14:49
By Sten Stovall Of DOW JONES NEWSWIRES LONDON (Dow Jones)--A collaboration between GlaxoSmithKline PLC (GSK) and two U.K. universities is looking to create faster-acting, safer medicines with a technology that prints active pharmaceutical ingredients onto a pill's surface which, if successfu
Read moreBroker tips: Glaxo, Micro Focus, DSG
24th Jun 2010 13:00
If GlaxoSmithKline pulls the trigger and launches its Lucozade brand in the US, it could be the key to unlocking shareholder value and rectify the stock's underperformance relative to fellow pharmaceuticals giant AstraZeneca, Panmure Gordon reckons. The size of the US market for soft drinks is arou
Read moreN AMERICAN MORNING BRIEFING: Recovery Fears To Hit Stocks
24th Jun 2010 11:44
DJIA Futures 10191.50 -33.50 -0.30% S&P 500 Futures 1081.60 -5.80 -0.50% Nasdaq Futures 1860.13 -13.63 -0.70% Above are as of 0615 ET FTSE 100 5144.85 -33.67 -0.70% Xetra DAX 6160.65 -43.87 -0.70% CAC40 3602.90 -38.89 -1.10% Above are as of 0
Read moreN AMERICAN MORNING BRIEFING: Recovery Fears To Hit Stocks
24th Jun 2010 11:43
DJIA Futures 10191.50 -33.50 -0.30% S&P 500 Futures 1081.60 -5.80 -0.50% Nasdaq Futures 1860.13 -13.63 -0.70% Above are as of 0615 ET FTSE 100 5144.85 -33.67 -0.70% Xetra DAX 6160.65 -43.87 -0.70% CAC40 3602.90 -38.89 -1.10% Above are as of 0
Read moreBroker snap: US Lucozade launch could revive Glaxo
24th Jun 2010 11:43
If GlaxoSmithKline pulls the trigger and launches its Lucozade brand in the US, it could be the key to unlocking shareholder value and rectify the stock's underperformance relative to fellow pharmaceuticals giant AstraZeneca, Panmure Gordon reckons. The size of the US market for soft drinks is arou
Read moreMARKET TALK: Genmab Lower On Arzerra Concerns
24th Jun 2010 10:25
0925 GMT [Dow Jones] Genmab (GEN.KO) trades -4.1% at DKK55.65 following news the U.K. National Institute for Health and Clinical Excellence won't recommend publicly-funded use of Genmab's and GlaxoSmithKline's (GSK) leukaemia drug Arzerra. Analyst Rune Majlund Dahl at Sydbank says the news hits Genm
Read moreGlaxoSmithKline To Launch Lucozade In US - Report
24th Jun 2010 07:54
LONDON (Dow Jones)--GlaxoSmithKline PLC (GSK) plans to launch Lucozade in the U.S., challenging PepsiCo Inc's (PEP) Gatorade and Coca-Cola Co's (KO) Powerade sports drinks, U.K. newspaper The Times reports Thursday. John Clarke, president of consumer healthcare at GSK, told the newspaper the com
Read moreGlaxoSmithKline: EU Grants Variation To Tyverb Conditional Marketing Approval
23rd Jun 2010 10:07
LONDON (Dow Jones)--GlaxoSmithKline PLC (GSK.LN) Wednesday confirmed that the European Commission (EC) has granted a variation to the conditional marketing authorization for Tyverb (lapatinib) in the European Union for a new therapeutic indication. MAIN FACTS: -Tyverb, in combination with an
Read more